Literature DB >> 29253489

Burden of hip fracture using disability-adjusted life-years: a pooled analysis of prospective cohorts in the CHANCES consortium.

Nikos Papadimitriou1, Konstantinos K Tsilidis2, Philippos Orfanos3, Vassiliki Benetou4, Evangelia E Ntzani5, Isabelle Soerjomataram6, Annemarie Künn-Nelen7, Ulrika Pettersson-Kymmer8, Sture Eriksson9, Hermann Brenner10, Ben Schöttker11, Kai-Uwe Saum12, Bernd Holleczek13, Francine D Grodstein14, Diane Feskanich14, Nicola Orsini15, Alicja Wolk15, Andrea Bellavia15, Tom Wilsgaard16, Lone Jørgensen17, Paolo Boffetta18, Dimitrios Trichopoulos19, Antonia Trichopoulou3.   

Abstract

BACKGROUND: No studies have estimated disability-adjusted life-years (DALYs) lost due to hip fractures using real-life follow-up cohort data. We aimed to quantify the burden of disease due to incident hip fracture using DALYs in prospective cohorts in the CHANCES consortium, and to calculate population attributable fractions based on DALYs for specific risk factors.
METHODS: We used data from six cohorts of participants aged 50 years or older at recruitment to calculate DALYs. We applied disability weights proposed by the National Osteoporosis Foundation and did a series of sensitivity analyses to examine the robustness of DALY estimates. We calculated population attributable fractions for smoking, body-mass index (BMI), physical activity, alcohol intake, type 2 diabetes and parity, use of hormone replacement therapy, and oral contraceptives in women. We calculated summary risk estimates across cohorts with pooled analysis and random-effects meta-analysis methods.
FINDINGS: 223 880 men and women were followed up for a mean of 13 years (SD 6). 7724 (3·5%) participants developed an incident hip fracture, of whom 413 (5·3%) died as a result. 5964 DALYs (27 per 1000 individuals) were lost due to hip fractures, 1230 (20·6%) of which were in the group aged 75-79 years. 4150 (69·6%) DALYs were attributed to disability. Current smoking was the risk factor responsible for the greatest hip fracture burden (7·5%, 95% CI 5·2-9·7) followed by physical inactivity (5·5%, 2·1-8·5), history of diabetes (2·8%, 2·1-4·0), and low to average BMI (2·0%, 1·4-2·7), whereas low alcohol consumption (0·01-2·5 g per day) and high BMI had a protective effect.
INTERPRETATION: Hip fracture can lead to a substantial loss of healthy life-years in elderly people. National public health policies should be strengthened to reduce hip fracture incidence and mortality. Primary prevention measures should be strengthened to prevent falls, and reduce smoking and a sedentary lifestyle. FUNDING: European Community's Seventh Framework Programme.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29253489     DOI: 10.1016/S2468-2667(17)30046-4

Source DB:  PubMed          Journal:  Lancet Public Health


  50 in total

1.  Residual Disability, Mortality, and Nursing Home Placement After Hip Fracture Over 2 Decades.

Authors:  Danielle S Abraham; Erik Barr; Glenn V Ostir; J Richard Hebel; Justine Golden; Ann L Gruber-Baldini; Jack M Guralnik; Marc C Hochberg; Denise L Orwig; Barbara Resnick; Jay S Magaziner
Journal:  Arch Phys Med Rehabil       Date:  2018-11-02       Impact factor: 3.966

2.  A new preoperative risk score for predicting mortality of elderly hip fracture patients: an external validation study.

Authors:  Zhicong Wang; Xi Chen; Ling Yang; Hong Wang; Wei Jiang; Yuehong Liu
Journal:  Aging Clin Exp Res       Date:  2021-01-24       Impact factor: 3.636

Review 3.  Clinical utility of virtual noncalcium dual-energy CT in imaging of the pelvis and hip.

Authors:  Francis I Baffour; Katrina N Glazebrook; Jonathan M Morris; Gregory J Michalak; Joel G Fletcher; Shuai Leng; Cynthia H McCollough
Journal:  Skeletal Radiol       Date:  2019-05-30       Impact factor: 2.199

4.  Building a cultural alliance for the prevention of fragility fractures among high risk older adults.

Authors:  Marta Baroni; Valentina Prenni; Carmelinda Ruggiero
Journal:  Ann Transl Med       Date:  2018-06

5.  A genome-wide scan for pleiotropy between bone mineral density and nonbone phenotypes.

Authors:  Maria A Christou; Georgios Ntritsos; Georgios Markozannes; Fotis Koskeridis; Spyros N Nikas; David Karasik; Douglas P Kiel; Evangelos Evangelou; Evangelia E Ntzani
Journal:  Bone Res       Date:  2020-07-01       Impact factor: 13.567

6.  Prospective validation of a rapid CT-based bone mineral density screening method using colored spinal images.

Authors:  Elliot Varney; Asser Abou Elkassem; Majid Khan; Ellen Parker; Todd Nichols; David Joyner; Seth T Lirette; Candace Howard-Claudio; Andrew D Smith
Journal:  Abdom Radiol (NY)       Date:  2020-10-12

7.  Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS.

Authors:  A Svedbom; F Borgstöm; E Hernlund; O Ström; V Alekna; M L Bianchi; P Clark; M D Curiel; H P Dimai; M Jürisson; R Kallikorm; M Lember; O Lesnyak; E McCloskey; K M Sanders; S Silverman; A Solodovnikov; M Tamulaitiene; T Thomas; N Toroptsova; A Uusküla; A N A Tosteson; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2017-12-11       Impact factor: 4.507

8.  Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.

Authors:  Salman Hussain; Ali Nasir Siddiqui; Anwar Habib; Md Sarfaraj Hussain; Abul Kalam Najmi
Journal:  Rheumatol Int       Date:  2018-08-29       Impact factor: 2.631

9.  The effect of low-trauma fracture on one-year mortality rate among privately insured adults with and without neurodevelopmental disabilities.

Authors:  Daniel G Whitney; Daniel Whibley; Karl J Jepsen
Journal:  Bone       Date:  2019-09-05       Impact factor: 4.398

Review 10.  Quality Measures and Quality Improvement Initiatives in Osteoporosis-an Update.

Authors:  S French; S Choden; Gabriela Schmajuk
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.